Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07474792
PHASE2

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

Sponsor: Oruka Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.

Official title: A Multicenter, Randomized, Double-Blinded, Placebo- Controlled, Dose-Range Finding Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis

Key Details

Gender

All

Age Range

18 Years - 79 Years

Study Type

INTERVENTIONAL

Enrollment

160

Start Date

2026-03-19

Completion Date

2029-04

Last Updated

2026-05-27

Healthy Volunteers

No

Interventions

DRUG

ORKA-002

ORKA-002 administered by subcutaneous (SC) injection

OTHER

Placebo

Placebo administered by subcutaneous (SC) injection

Locations (31)

Oruka Therapeutics Investigative Site

Birmingham, Alabama, United States

Oruka Therapeutics Investigative Site

Fountain Valley, California, United States

Oruka Therapeutics Investigative Site

Los Angeles, California, United States

Oruka Therapeutics Investigative Site

San Diego, California, United States

Oruka Therapeutics Investigative Site

Santa Ana, California, United States

Oruka Therapeutics Investigative Site

Santa Monica, California, United States

Oruka Therapeutics Investigative Site

Cromwell, Connecticut, United States

Oruka Therapeutics Investigative Site

Coral Gables, Florida, United States

Oruka Therapeutics Investigative Site

Milford, Massachusetts, United States

Oruka Therapeutics Investigative Site

Ann Arbor, Michigan, United States

Oruka Therapeutics Investigative Site

Detroit, Michigan, United States

Oruka Therapeutics Investigative Site

Warren, Michigan, United States

Oruka Therapeutics Investigative Site

New Brighton, Minnesota, United States

Oruka Therapeutics Investigative Site

Omaha, Nebraska, United States

Oruka Therapeutics Investigative Site

New York, New York, United States

Oruka Therapeutics Investigative Site

Wilmington, North Carolina, United States

Oruka Therapeutics Investigative Site

Bexley, Ohio, United States

Oruka Therapeutics Investigative Site

Portland, Oregon, United States

Oruka Therapeutics Investigative Site

Warrenton, Oregon, United States

Oruka Therapeutics Investigative Site

Dallas, Texas, United States

Oruka Therapeutics Investigative Site

Dallas, Texas, United States

Oruka Therapeutics Investigative Site

Mill Creek, Washington, United States

Oruka Therapeutics Investigative Site

Edmonton, Alberta, Canada

Oruka Therapeutics Investigative Site

Surrey, British Columbia, Canada

Oruka Therapeutics Investigative Site

Barrie, Ontario, Canada

Oruka Therapeutics Investigative Site

London, Ontario, Canada

Oruka Therapeutics Investigative Site

North Bay, Ontario, Canada

Oruka Therapeutics Investigative Site

Peterborough, Ontario, Canada

Oruka Therapeutics Investigative Site

Toronto, Ontario, Canada

Oruka Therapeutics Investigative Site

Waterloo, Ontario, Canada

Oruka Therapeutics Investigative Site

Saskatoon, Saskatchewan, Canada